Raymond James Maintains Third Harmonic Bio(THRD.US) With Hold Rating
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Raises Target Price to $5.23
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Maintains Target Price $5
Stifel Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Maintains Target Price $5
Third Harmonic Bio Cut to Hold From Buy by Stifel
Third Harmonic Bio Analyst Ratings
Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23
Stifel Downgrades Third Harmonic Bio(THRD.US) to Hold Rating, Cuts Target Price to $5
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Maintains Target Price $5
Third Harmonic Bio Price Target Cut to $5.00/Share From $20.00 by Morgan Stanley
Third Harmonic Bio Cut to Equal-Weight From Overweight by Morgan Stanley
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns
Morgan Stanley Downgrades Third Harmonic Bio(THRD.US) to Hold Rating, Cuts Target Price to $5
LifeSci Capital Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Announces Target Price $5.5
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns
Raymond James Downgrades Third Harmonic Bio(THRD.US) to Hold Rating
Third Harmonic Bio Analyst Ratings
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Maintains Target Price $20
Buy Rating on Third Harmonic Bio: Anticipated Catalysts and De-risking Phase 1 Data for THB335
Jefferies Maintains Third Harmonic Bio(THRD.US) With Hold Rating, Raises Target Price to $7